Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Standard first-line treatment for Stage IC-IV ovarian cancer is currently a platinum agent or a combination of a platinum agent with a taxane. The use of a taxane compound in addition to single-agent platinum is increasingly preferred to platinum alone. In countries such as the UK, the taxane paclitaxel has been approved by the government for first-line use. However, it has yet to receive US Food and Drug Administration approval in the USA for use in this context. Typically, in countries such as the UK, patients with advanced ovarian cancer receive a combination of paclitaxel and carboplatin first line, both drugs given 3-weekly by intravenous infusion. Subsequent trials have demonstrated that the second-generation taxane docetaxel can be used as a substitute for paclitaxel; sharing many of its actions but with a different toxicity profile. However, docetaxel has not yet received approval for standard use. Here, the clinical development of docetaxel and its present and future place in the management of ovarian cancer is discussed.

Original publication

DOI

10.1586/14737140.5.2.203

Type

Journal article

Journal

Expert Rev Anticancer Ther

Publication Date

04/2005

Volume

5

Pages

203 - 214

Keywords

Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Docetaxel, Drug Approval, Female, Humans, Neoplasm Recurrence, Local, Neoplasm Staging, Ovarian Neoplasms, Taxoids, United Kingdom, United States